193 related articles for article (PubMed ID: 18849561)
1. Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy.
Wiese D; Lashner B; Seidner D
Nutr Clin Pract; 2008; 23(5):551-6. PubMed ID: 18849561
[TBL] [Abstract][Full Text] [Related]
2. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone.
Azcue M; Rashid M; Griffiths A; Pencharz PB
Gut; 1997 Aug; 41(2):203-8. PubMed ID: 9301499
[TBL] [Abstract][Full Text] [Related]
3. Impact of Disease Activity on Resting Energy Expenditure and Body Composition in Adult Crohn's Disease: A Prospective Longitudinal Assessment.
Gong J; Zuo L; Guo Z; Zhang L; Li Y; Gu L; Zhao J; Cao L; Zhu W; Li N; Li J
JPEN J Parenter Enteral Nutr; 2015 Aug; 39(6):713-8. PubMed ID: 24668997
[TBL] [Abstract][Full Text] [Related]
4. Malabsorption is a major contributor to underweight in Crohn's disease patients in remission.
Vaisman N; Dotan I; Halack A; Niv E
Nutrition; 2006 Sep; 22(9):855-9. PubMed ID: 16928471
[TBL] [Abstract][Full Text] [Related]
5. Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients.
Diamanti A; Basso MS; Gambarara M; Papadatou B; Bracci F; Noto C; Castro M
Int J Colorectal Dis; 2009 Jan; 24(1):19-25. PubMed ID: 18797887
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
Eivindson M; Grønbaek H; Skogstrand K; Thorsen P; Frystyk J; Flyvbjerg A; Dahlerup JF
Scand J Gastroenterol; 2007 Apr; 42(4):464-70. PubMed ID: 17454856
[TBL] [Abstract][Full Text] [Related]
7. The Effect of anti-TNFα Induction Therapy on the Nutritional Status and Dietary Intake in Inflammatory Bowel Disease.
Csontos ÁA; Molnár A; Piri Z; Katona B; Dakó S; Pálfi E; Miheller P
J Gastrointestin Liver Dis; 2016 Mar; 25(1):49-56. PubMed ID: 27014753
[TBL] [Abstract][Full Text] [Related]
8. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
9. Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy.
Emerenziani S; Biancone L; Guarino MPL; Balestrieri P; Stasi E; Ribolsi M; Rescio MP; Altomare A; Cocca S; Pallone F; Cicala M
Dig Liver Dis; 2017 May; 49(5):495-499. PubMed ID: 28096060
[TBL] [Abstract][Full Text] [Related]
10. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.
Nakahigashi M; Yamamoto T
Cytokine; 2011 Nov; 56(2):531-5. PubMed ID: 21820319
[TBL] [Abstract][Full Text] [Related]
11. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
12. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.
Lönnkvist MH; Theodorsson E; Holst M; Ljung T; Hellström PM
Scand J Gastroenterol; 2011 Apr; 46(4):420-7. PubMed ID: 21114432
[TBL] [Abstract][Full Text] [Related]
13. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.
Van Assche G; Herrmann KA; Louis E; Everett SM; Colombel JF; Rahier JF; Vanbeckevoort D; Meunier P; Tolan D; Ernst O; Rutgeerts P; Vermeire S; Aerden I; Oortwijn A; Ochsenkühn T
J Crohns Colitis; 2013 Dec; 7(12):950-7. PubMed ID: 23411006
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
Sprakes MB; Ford AC; Warren L; Greer D; Hamlin J
J Crohns Colitis; 2012 Mar; 6(2):143-53. PubMed ID: 22325168
[TBL] [Abstract][Full Text] [Related]
15. Impact of enteral nutrition on energy metabolism in patients with Crohn's disease.
Zhao J; Dong JN; Gong JF; Wang HG; Li Y; Zhang L; Zuo LG; Feng Y; Gu LL; Li N; Li JS; Zhu WM
World J Gastroenterol; 2015 Jan; 21(4):1299-304. PubMed ID: 25632205
[TBL] [Abstract][Full Text] [Related]
16. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.
Sumi R; Nakajima K; Iijima H; Wasa M; Shinzaki S; Nezu R; Inoue Y; Ito T
Surg Today; 2016 Aug; 46(8):922-9. PubMed ID: 26438200
[TBL] [Abstract][Full Text] [Related]
17. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
Szabó D; Kökönyei G; Arató A; Dezsőfi A; Molnár K; Müller KE; Lakatos PL; Papp M; Lovász BD; Golovics PA; Cseh A; Veres G
J Crohns Colitis; 2014 Aug; 8(8):747-55. PubMed ID: 24434181
[TBL] [Abstract][Full Text] [Related]
18. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
19. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
[TBL] [Abstract][Full Text] [Related]
20. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease.
Steiner SJ; Pfefferkorn MD; Fitzgerald JF; Denne SC
Pediatr Res; 2008 Dec; 64(6):673-6. PubMed ID: 18679167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
